Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
- PMID: 22081500
- DOI: 10.1002/mds.23795
Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
Abstract
Parkinson's disease (PD), one of the most frequent neurodegenerative disorders, is no longer considered a complex motor disorder characterized by extrapyramidal symptoms, but a progressive multisystem or-more correctly-multiorgan disease with variegated neurological and nonmotor deficiencies. It is morphologically featured not only by the degeneration of the dopaminergic nigrostriatal system, responsible for the core motor deficits, but by multifocal involvement of the central, peripheral and autonomic nervous system and other organs associated with widespread occurrence of Lewy bodies and dystrophic Lewy neurites. This results from deposition of abnormal α-synuclein (αSyn), the major protein marker of PD, and other synucleinopathies. Recent research has improved both the clinical and neuropathological diagnostic criteria of PD; it has further provided insights into the development and staging of αSyn and Lewy pathologies and has been useful in understanding the pathogenesis of PD. However, many challenges remain, for example, the role of Lewy bodies and the neurobiology of axons in the course of neurodegeneration, the relation between αSyn, Lewy pathology, and clinical deficits, as well as the interaction between αSyn and other pathologic proteins. Although genetic and experimental models have contributed to exploring the causes, pathomechanisms, and treatment options of PD, there is still a lack of an optimal animal model, and the etiology of this devastating disease is far from being elucidated.
Copyright © 2011 Movement Disorder Society.
Similar articles
-
The pathomechanisms underlying Parkinson's disease.Expert Rev Neurother. 2014 Feb;14(2):199-215. doi: 10.1586/14737175.2014.877842. Expert Rev Neurother. 2014. PMID: 24471711 Review.
-
Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.Neuroscience. 2009 Jun 2;160(4):796-804. doi: 10.1016/j.neuroscience.2009.03.002. Epub 2009 Mar 9. Neuroscience. 2009. PMID: 19272424
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
-
A critical reappraisal of current staging of Lewy-related pathology in human brain.Acta Neuropathol. 2008 Jul;116(1):1-16. doi: 10.1007/s00401-008-0406-y. Epub 2008 Jul 1. Acta Neuropathol. 2008. PMID: 18592254 Review.
-
Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.Neuron. 2006 Oct 5;52(1):33-8. doi: 10.1016/j.neuron.2006.09.026. Neuron. 2006. PMID: 17015225 Review.
Cited by
-
Changes of retina are not involved in the genesis of visual hallucinations in Parkinson's disease.Parkinsons Dis. 2015;2015:709191. doi: 10.1155/2015/709191. Epub 2015 Feb 3. Parkinsons Dis. 2015. PMID: 25722916 Free PMC article.
-
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.Brain. 2013 Sep;136(Pt 9):2697-706. doi: 10.1093/brain/awt188. Epub 2013 Jul 10. Brain. 2013. PMID: 23842566 Free PMC article.
-
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.Brain. 2013 Aug;136(Pt 8):2419-31. doi: 10.1093/brain/awt192. Brain. 2013. PMID: 23884810 Free PMC article.
-
Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats.Neurochem Res. 2018 Nov;43(11):2132-2140. doi: 10.1007/s11064-018-2638-0. Epub 2018 Sep 28. Neurochem Res. 2018. PMID: 30267378
-
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice.Nat Rev Neurol. 2023 Jun;19(6):333-345. doi: 10.1038/s41582-023-00802-5. Epub 2023 May 4. Nat Rev Neurol. 2023. PMID: 37142796 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical